PMV Pharmaceuticals (PMVP) Projected to Announce Earnings on Wednesday

PMV Pharmaceuticals (NASDAQ:PMVP) will likely be announcing its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect PMV Pharmaceuticals to announce earnings of ($0.31) per share for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

PMV Pharmaceuticals (NASDAQ:PMVP) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.05. On average, analysts expect PMV Pharmaceuticals to post ($1.20) EPS for the current fiscal year and ($0.81) EPS for the next fiscal year.

PMV Pharmaceuticals Stock Up 1.7%

Shares of NASDAQ PMVP opened at $1.40 on Wednesday. PMV Pharmaceuticals has a fifty-two week low of $1.02 and a fifty-two week high of $1.91. The firm has a market cap of $75.00 million, a PE ratio of -0.99 and a beta of 1.52. The business has a 50 day moving average price of $1.39 and a two-hundred day moving average price of $1.30.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Weiss Ratings raised shares of PMV Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 24th. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of PMV Pharmaceuticals in a report on Friday, September 4th. LADENBURG THALM/SH SH began coverage on PMV Pharmaceuticals in a report on Wednesday, July 8th. They issued a “buy” rating and a $3.00 price objective on the stock. Finally, Wall Street Zen upgraded PMV Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $4.33.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc is a clinical-stage precision oncology company focused on developing therapies that target cancer-causing mutations in the tumor suppressor protein p53. The company aims to discover and develop small-molecule medicines designed to restore the normal tumor-suppressing function of mutant p53 proteins.

PMV’s lead product candidate is rezatapopt, also known as PC14586, an investigational oral therapy designed to selectively target the p53 Y220C mutation. This mutation occurs in a range of solid tumors, and rezatapopt is being evaluated for its potential to reactivate the altered p53 protein and inhibit cancer-cell growth.

Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals is advancing rezatapopt through clinical development in patients with advanced solid tumors containing the p53 Y220C mutation.